{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T10:00:55Z","timestamp":1781085655098,"version":"3.54.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pancreatic cancer (PC) remains largely refractory to immune checkpoint inhibitors (ICIs), especially in the prevalent microsatellite-stable (MSS) subtype. However, combination strategies of ICIs with chemotherapy have largely failed in MSS PC, highlighting an urgent need for novel immunotherapeutic approaches. Cadonilimab is a novel programmed death protein 1(PD-1)\/cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) bispecific antibody designed to remodel the immunosuppressive tumor microenvironment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report description<\/jats:title>\n                    <jats:p>We report an exceptional and durable response to cadonilimab plus chemotherapy in a patient with metastatic MSS pancreatic cystadenocarcinoma (PCAC). Microsatellite stability was shown by immunohistochemistry with intact expression of all four mismatch repair proteins (MLH1, MSH2, MSH6, PMS2) and confirmed by next-generation sequencing (NGS). Following disease progression on first-line gemcitabine\/nab-paclitaxel and transarterial chemoembolization (TACE), the patient subsequently received second-line therapy with cadonilimab combined with nab-paclitaxel and oxaliplatin. Notably, within two months of treatment initiation, the patient achieved near-complete remission (near-CR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, with an 89.9% reduction in the sum of target lesion diameters. Despite discontinuing anticancer therapy after 4 cycles due to grade 3 bone marrow suppression, which subsequently evolved into and has been maintained as a complete response (CR) for over 30 months, with the primary endpoint of progression-free survival (PFS) not yet reached.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case provides pioneering clinical evidence that cadonilimab, in combination with chemotherapy, can induce profound and durable remission in MSS PCAC, challenging current paradigms of ICI resistance and supporting the further development of bispecific antibody strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1735785","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T06:09:48Z","timestamp":1780034988000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Converting an immunologically \u201ccold\u201d tumor: exceptional response to cadonilimab plus chemotherapy in microsatellite-stable pancreatic cystadenocarcinoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Chunxiao","family":"Ni","sequence":"first","affiliation":[{"name":"Department of Minimally Invasive Oncology, Tai\u2019an City Central Hospital","place":["Tai\u2019an, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaju","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Yantai Yuhuangding Hospital","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tai\u2019an City Central Hospital","place":["Tai\u2019an, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaju","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tai\u2019an City Central Hospital","place":["Tai\u2019an, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA: A Cancer J For Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000750","article-title":"Simple mucinous cyst\" of the pancreas: A clinicopathologic analysis of 39 examples of a diagnostically challenging entity distinct from intraductal papillary mucinous neoplasms and mucinous cystic neoplasms","volume":"41","author":"Krasinskas","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.36018","article-title":"Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas","volume":"123","author":"Kim","year":"2002","journal-title":"Gastroenterology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1001\/jamasurg.2016.3598","article-title":"Association of preoperative risk factors with Malignancy in pancreatic mucinous cystic neoplasms: A multicenter study","volume":"152","author":"Postlewait","year":"2017","journal-title":"JAMA Surg"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.985184","article-title":"Cancer-specific survival and metastasis in pancreatic mucinous cystadenocarcinoma: A SEER-based cohort study","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ijsu.2016.09.017","article-title":"Pancreatic mucinous cystadenocarcinoma: Epidemiology and outcomes","volume":"35","author":"Doulamis","year":"2016","journal-title":"Int J Surg"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.6730-20","article-title":"Dramatic response to carboplatin plus paclitaxel in pancreatic mucinous cystadenocarcinoma with liver metastasis","volume":"60","author":"Oda","year":"2021","journal-title":"Internal Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/mpa.0000000000001063","article-title":"Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis","volume":"47","author":"Brunetti","year":"2018","journal-title":"Pancreas"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.22544127.v1","article-title":"Supplementary figures from PD-1\/PD-L1\u2013associated immunoarchitectural patterns stratify pancreatic cancer patients into prognostic\/predictive subgroups","volume":"9","author":"Karamitopoulou","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-022-02273-w","article-title":"Combination therapy for pancreatic cancer: Anti-Pd-(l)1-based strategy","volume":"41","author":"Lingyue","year":"2022","journal-title":"J Exp Clin Cancer Res: CR"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-3452","article-title":"Facts and hopes in immunotherapy of pancreatic cancer","volume":"28","author":"Bockorny","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188384","article-title":"Killing the \"BAD\": Challenges for immunotherapy in pancreatic cancer","volume":"1874","author":"Li","year":"2020","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054824","article-title":"Pancreatic tumors and immature immunosuppressive myeloid cells in blood and spleen: Role of inhibitory co-stimulatory molecules PDL1 and CTLA4. An in vivo and in vitro study","volume":"8","author":"Basso","year":"2013","journal-title":"PloS One"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2180794","article-title":"Cadonilimab, a tetravalent PD-1\/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity","volume":"15","author":"Pang","year":"2023","journal-title":"mAbs"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(22)00235-7","article-title":"The tumour immune microenvironment and microbiome of pancreatic intraductal papillary mucinous neoplasms","volume":"7","author":"Pollini","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s42256-024-00868-w","article-title":"A transformer-based weakly supervised computational pathology method for clinical-grade diagnosis and molecular marker discovery of gliomas","volume":"6","author":"Jiang","year":"2024","journal-title":"Nat Mach Intell"},{"key":"B17","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1186\/s12951-025-03868-z","article-title":"A high-affinity CEA-targeted nanobody for (68)Ga PET imaging and (177)Lu-based radioisotope therapy: Preclinical and first-in-human evaluation","volume":"23","author":"Zhang","year":"2025","journal-title":"J Nanobiotechnol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.semcancer.2023.09.004","article-title":"Immune evasion on the nanoscale: Small extracellular vesicles in pancreatic ductal adenocarcinoma immunity","volume":"96","author":"Fyfe","year":"2023","journal-title":"Semin Cancer Biol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101751","article-title":"Thymosin A1 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy","volume":"5","author":"Liu","year":"2024","journal-title":"Cell Rep Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2147\/jir.s499403","article-title":"The benefits and safety of monoclonal antibodies: Implications for cancer immunotherapy","volume":"18","author":"Zhang","year":"2025","journal-title":"J Inflammation Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v16.i4.102418","article-title":"Multiple primary tumors patient developed microsatellite stable gastric cancer after cadonilimab treatment for liver cancer: A case report","volume":"16","author":"Luo","year":"2025","journal-title":"World J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1238667","article-title":"The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): A phase Ib\/II single-arm clinical trial","volume":"14","author":"Qiao","year":"2023","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1049518","article-title":"Patients with positive HER-2 amplification advanced gastroesophageal junction cancer achieved complete response with combined chemotherapy of AK104\/cadonilimab (PD-1\/CTLA-4 bispecific): A case report","volume":"13","author":"Peng","year":"2022","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41392-025-02292-x","article-title":"Serine\/threonine\/tyrosine kinase 1 drives pancreatic carcinogenesis via GSK3beta sequestration-mediated Wnt\/beta-catenin pathway hyperactivation","volume":"10","author":"Zhou","year":"2025","journal-title":"Signal Transd Targ Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: Clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padron","year":"2022","journal-title":"Nat Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbaf580","article-title":"Deep learning-based fusion of nuclear segmentation features for microsatellite instability and tumor mutational burden prediction in digestive tract cancers: A multicenter validation study","volume":"26","author":"Zhang","year":"2025","journal-title":"Briefings Bioinf"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-334361","article-title":"Histone lactylation-driven feedback loop modulates cholesterol-linked immunosuppression in pancreatic cancer","author":"Yang","year":"2025","journal-title":"Gut"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202504064","article-title":"Pancreatic cancer-derived extracellular vesicles enriched with miR-223-5p promote skeletal muscle wasting associated with cachexia","volume":"12","author":"Xu","year":"2025","journal-title":"Adv Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/08923973.2024.2402338","article-title":"Clinical features, treatment, and outcome of nivolumab-induced cholangitis","volume":"46","author":"He","year":"2024","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-021-03205-3","article-title":"Histo-molecular characterization of pancreatic cancer with microsatellite instability: Intra-tumor heterogeneity, B2M inactivation, and the importance of metastatic sites","volume":"480","author":"Luchini","year":"2022","journal-title":"Virchows Archiv: Int J Pathol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.ircmb.2023.10.002","article-title":"Epigenetic therapeutic strategies in pancreatic cancer","volume":"383","author":"Orlacchio","year":"2024","journal-title":"Int Rev Cell Mol Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58553-4","article-title":"Gut commensal Bifidobacterium-derived extracellular vesicles modulate the therapeutic effects of anti-Pd-1 in lung cancer","volume":"16","author":"Preet","year":"2025","journal-title":"Nat Commun"}],"updated-by":[{"DOI":"10.3389\/fimmu.2026.1897164","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1735785\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T09:23:01Z","timestamp":1781083381000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1735785\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2026.1735785"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1735785","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"article-number":"1735785"}}